Shivan Sivakumar, Professor of Translational Oncology at the University of Birmingham, shared on LinkedIn:
”I have been lucky enough to be asked by the New England Journal of Medicine to write the editorial to the recent Rasolute 302 trial which has the potential to change the outcomes of patients with pancreatic cancer.
My summary is below including what the trial showed and where I see the future of pancreatic cancer going.
Very exciting times!”
Title: Breaking the RAS Barrier in Pancreatic Cancer
Authors: Shivan Sivakumar
Other articles about Pancreatic Cancer on OncoDaily.